Cancer Discov. 2014 Jan;4(1):OF2. doi: 10.1158/2159-8290.CD-NB2013-168. Epub 2013 Dec 5.
In a phase III study, Merck's new V503 human papillomavirus (HPV) vaccine prevented 97% of high-grade, precancerous vaginal, vulvar, and cervical disease caused by HPV types 31, 33, 45, 52, and 58. The new vaccine also generated immune responses to HPV types 6, 11, 16, and 18 that were as good as or better than those generated by the company's Gardasil vaccine.
在一项 III 期研究中,默克公司的新型 V503 人乳头瘤病毒(HPV)疫苗预防了由 HPV 型 31、33、45、52 和 58 引起的 97%的高级别、癌前阴道、外阴和宫颈疾病。该新型疫苗还对 HPV 型 6、11、16 和 18 产生了免疫反应,其效果与该公司的佳达修疫苗相当或更好。